President William Lai said Taiwan aims to make biomedicine its next
industrial pillar after semiconductors. Speaking at the Presidential Office to
leaders of award-winning biotech firms, Lai said their success highlights
Taiwan’s strong R&D and growing industry diversity.
The sector reached a record US$25.6 billion last year. Lai pledged legal and
policy support to boost competitiveness and resilience amid global
challenges such as COVID-19, the U.S. Inflation Reduction Act, and new
tariffs.
Under the “National Project of Hope,” the Cabinet’s Bio Taiwan Committee
will oversee development of the biomedicine sector. New regulations,
including the Human Biobank Management Act and updated drug and device
review systems, are designed to align Taiwan with global standards.
Lai also called for greater private participation in the US$310 million Smart
Medicine Investment Project and promoted AI adoption to build robust, high-
quality biotech supply chains.
